[Frusemide plus doxazosin therapy for nocturia in patients with BPH/LUTS].

Abstract

OBJECTIVE:

To determine the efficacy and safety of a diuretic agent, frusemide, combined with doxazosin in the treatment of nocturia in patients with benign prostate hyperplasia / lower urinary tract symptoms (BPH/LUTS).

METHODS:

Sixty-four BPH/LUTS patients with nocturia were equally randomized into two groups, one treated with doxazosin (4 mg/d), and the other with frusemide (40 mg/d) and doxazosin (4 mg/d), given 6 h before sleep, both for 4 weeks. Urine volume, IPSS, QOL, serum electrolytes, plasma osmolality were recorded and compared between the two groups before and after the treatment.

RESULTS:

Compared with the doxazosin group, the frusemide plus doxazosin group showed significantly reduced nocturia frequency (P < 0.01), increased daytime urine output (P < 0.01), decreased nocturia urine output (P < 0.01), unchanged total urine output (P > 0.05), improved IPSS and QOL (P < 0.05, P < 0.01), but with no remarkable differences in the levels of serum sodium, potassium, chlorine, and osmotic pressure (P > 0.05).

CONCLUSION:

Four-week treatment with frusemide plus doxazosin was safe and effective for nocturia in patients with BPH/LUTS.

• Authors: Shi-yong Huang, Shao-xing Zhu, Bang-wei Zeng, De-sheng Zhu, Rong-jin Fang
• Journal: Zhonghua nan ke xue = National journal of andrology (Zhonghua Nan Ke Xue) Vol. 16 Issue 9 Pg. 807-10 (Sep 2010) ISSN: 1009-3591 [Print] China
• PMID: 21171265 (Publication Type: English Abstract, Journal Article, Randomized Controlled Trial)

Chemical References

• Furosemide
• Doxazosin

Topics

• Aged
• Aged, 80 and over
• Doxazosin (therapeutic use)
• Furosemide (therapeutic use)
• Humans
• Male
• Middle Aged
• Nocturia (drug therapy, etiology)
• Prostatic Hyperplasia (complications, drug therapy)